| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 25024 |
| Drug | Semaglutide |
| Brand | Wegovy® |
| Indication | Semaglutide (Wegovy®) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (BMI) of • ≥30kg/m2 (obesity), or • ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. |
| Assessment Process | |
| Rapid review commissioned | 21/03/2025 |
| Rapid review completed | 14/05/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of semaglutide (Wegovy®) for this indication compared with the current standard of care. |
| Full HTA commissioned by the HSE | 29/05/2025 |
| Pre-submission consultation with Applicant | 03/09/2025 |
| Full submission received from Applicant | 23/02/2026 |
| Preliminary review sent to Applicant | 27/05/2026 |
| NCPE assessment re-commenced | 26/06/2026 |
| Factual accuracy sent to Applicant | 21/09/2026 |
| NCPE assessment re-commenced | 25/09/2026 |
| NCPE assessment completed | 13/10/2026 |
| NCPE assessment outcome | The NCPE recommends that semaglutide (Wegovy®) be considered for reimbursement for the indication under assessment*. Budget impact estimates associated with semaglutide are substantial. Consideration will need to be given, regarding the affordability of semaglutide, when making a decision regarding reimbursement. |
*Next steps: The NCPE Assessment Report and recommendation and Patient Organisation submission, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health Pricing and Supply of Medical Goods Act 2013.
Further information on this process may be found here.
Please see the HSE Pricing and Reimbursement Tracker for any updates on the reimbursement status of this drug.
HSE Pricing and Reimbursement Tracker